Previous 10 | Next 10 |
ADC Therapeutics (ADCT) announces that Avid Bioservices, a contract development and manufacturing organization will serve as the commercial manufacturer for the humanized monoclonal antibody portion of Zynlonta (loncastuximab tesirine-lpyl).ADCT shares up 2.2% premarket tradin...
TUSTIN, Calif., May 25, 2021 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to bi...
Posters to highlight ZYNLONTA ™ LOTIS-2 subgroup analyses, ZYNLONTA ™ LOTIS-5 confirmatory trial and Cami in advanced solid tumors ADC Therapeutics SA (NYSE:ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug c...
ADC Therapeutics SA (NYSE:ADCT) traded at a new 52-week low today of $20.12. This new low was reached on below average trading volume as 131,000 shares traded hands, while the average 30-day volume is approximately 363,000 shares. ADC Therapeutics SA has overhead space with shares priced...
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced the receipt of the $50 million second tranche under its convertible credit fa...
The following slide deck was published by ADC Therapeutics SA in conjunction with this event. For further details see: ADC Therapeutics SA (ADCT) Investor Presentation - Slideshow
ADC Therapeutics (ADCT) announces that results of Phase 2 LOTIS-2 trial evaluating the safety and efficacy of single-agent ZYNLONTA in adult patients with relapsed or refractory diffuse large B-cell lymphoma ((DLBCL)) following two or more systemic treatments have been published in The Lancet...
Recent FDA approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) was based on data from LOTIS-2 ZYNLONTA ™ demonstrated substantial single-agent activity, durable responses and an acceptable safety profile in broad population of difficult-to-treat patients with...
Shares of ADC Therapeutics SA (NYSE:ADCT) traded today at $20.54, breaking its 52-week low. This new low was reached on below average trading volume as 197,000 shares traded hands, while the average 30-day volume is approximately 362,000 shares. ADC Therapeutics SA is a United States-bas...
ADC Therapeutics SA (ADCT) Q1 2021 Earnings Conference Call May 06, 2021, 08:30 ET Company Participants Amanda Hamilton - IR Officer Christopher Martin - Co-Founder, CEO & Director Jennifer Herron - Chief Commercial Officer & SVP Jay Feingold - Chief Medical Officer, Head, Oncology Cl...
News, Short Squeeze, Breakout and More Instantly...
£90m ($114m) series A co-led by new leading life science investors Novo Holdings and Abingworth Additional new investors British Patient Capital, Cancer Research Horizons and Lilly participated alongside founding investors Brandon Capital and Sofinnova Partners Funds will be used to ...
LAUSANNE, Switzerland, June 27, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company is set to join the Russell 2000 ® Index and the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Indexes annual reconstitution, ef...